Skip to content

PeerfordResearch intelligence

Countries
Institutions
Researchers
Fields
Rankings
Compare
Commons

Search institutions, scholars, countries and publications

Countries
Institutions
Researchers
Fields
Rankings
Compare

CommonsWhere researchers talk about their work

Search institutions, scholars, countries and publications

Every figure here is counted by Peerford from the works themselves, the same way for every institution.

Browse

Countries
Institutions
Researchers
Fields
Rankings
Commons, for researchers

About

How Peerford counts
Compare institutions
Privacy
Terms of use

Contact

hello@peerford.com
https://wa.me/peerford · WhatsApp

Language

English
FrançaisFrench
PortuguêsPortuguese
العربيةArabic

Theme

SystemLightDark

Asmau Nasir Hamza · Peerford

Ahmadu Bello University / Scholars

AH

Asmau Nasir Hamza

Ahmadu Bello University

Publishing since 2025

Genetics
Hematology
Organic Chemistry

Download CV:PDF Word
Who they write with Where their co-authors are Every publication
Is this you? Sign in to edit your profile

Publications: 12025
Citations: 0to those papers
h-index: 0i10-index 0
Field-weighted impact: 0.001.00 is the world average
World top 10%: 0%0 of 1 scored papers
Open access: 100%1 papers free to read

By year

Papers, and the citations to them

Publications, left axisCitations to that year’s papers, right axis2026 still in progress

What they work on

From the classification of each paper

Subfields

Genetics1100%
Hematology1100%
Organic Chemistry1100%

Health Sciences

Publications

1 in all

Novel Chalcone Derivatives as Potent Lyn Tyrosine Kinase Inhibitors: A Promising In-Silico Approach for Targeted Therapy in Triple-Negative Breast Cancer
2025PublicationOpen access0 citations10.3390/ecsoc-29-26887

Life Sciences

Physical Sciences

Topics most written on

Chronic Myeloid Leukemia Treatments1
Estrogen and related hormone effects1
Synthesis and biological activity1

How it can be read

100% free to read

Gold 1 · 100%In an open-access journal

Most cited

Novel Chalcone Derivatives as Potent Lyn Tyrosine Kinase Inhibitors: A Promising In-Silico Approach for Targeted Therapy in Triple-Negative Breast Cancer
20250 citationsOpen access · Gold